期刊
BIOMATERIALS
卷 104, 期 -, 页码 269-278出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2016.07.015
关键词
Fluorescent carbon nanoparticle; Gene regulation; Cancer therapy; Plk1 gene; Small interfering RNA
资金
- National Science Foundation of China [81361140345, 31470911, 51373043, 21222502]
- CAS [XDA09030305, XDA09030307]
- CAS/SAFEA International Partnership Program for Creative Research Teams
We report fluorescent carbon nanoparticle (FCN)-based small interfering RNA (siRNA) conjugates (C-siRNA) for gene regulation and cancer therapy. The C-siRNA has a core of chitosan-derived FCN and a shell of siRNA, and can down-regulate the expression of polo-like kinase-1 (Plk1), a master regulator of mitosis, via siRNA targeting Plk1 (siPlk1), for cancer therapy. The required amount of the FCNs is only similar to 1/30 of that of the gold nanoparticles in delivering equal amount of siRNA. The C-siPlk1 led to similar to 80% knockdown of cellular Plk1 mRNA in A375 cells, and induced apoptosis of the A375 cells (31.9%) and MCF-7 cells (20.33%), much higher than those by commercial nonviral gene delivery vectors, such as Lipofectamine 2000 in both cell lines (apoptosis rate < 10%). After the C-siPlk1 was administrated to A375 tumor-bearing mice intravenously, the tumor volume was less than 1/11 of the control groups. The C-siRNA can thus be powerful tools for gene delivery and gene therapy. (C) 2016 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据